Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

@article{Priotto2009NifurtimoxeflornithineCT,
  title={Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial},
  author={G. Priotto and S. Kasparian and W. Mutombo and D. Ngouama and V. Kande},
  journal={The Lancet},
  year={2009},
  volume={374},
  pages={56-64}
}
  • G. Priotto, S. Kasparian, +2 authors V. Kande
  • Published 2009
  • Medicine
  • The Lancet
  • BACKGROUND Human African trypanosomiasis (HAT; sleeping sickness) caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients with second-stage disease are toxic, ineffective, or impractical. We assessed the efficacy and safety of nifurtimox-eflornithine combination therapy (NECT) for second-stage disease compared with the standard eflornithine regimen. METHODS A multicentre, randomised, open-label, active control, phase III, non-inferiority trial was… CONTINUE READING
    397 Citations
    Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.
    • E. Alirol, D. Schrumpf, +4 authors F. Chappuis
    • Medicine
    • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
    • 2013
    • 71
    • PDF
    Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis.
    • 25
    • Highly Influenced
    • PDF
    Evaluation of trypanocidal drugs used for human African trypanosomosis against Trypanosoma lewisi
    • 11
    • Highly Influenced
    • PDF
    Chemotherapy for second-stage human African trypanosomiasis.
    • 54
    • PDF

    References

    SHOWING 1-10 OF 29 REFERENCES
    Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
    • 126
    • PDF
    Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial.
    • 65
    • PDF
    An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire.
    • 56
    High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire.
    • 65
    Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.
    • 125
    • PDF